Abstract:Background: Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Committee. Methods: Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO BC experts, the CSCO BC guidelines determine the levels of recommendations for clinical application. Results: For human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a combination of trastuzumab and pertuzumab regimen were recommended as Level I recommendation for neoadjuvant and first line metastatic breast cancer. Pyrotinib is also recommended as Level I recommendation in first line and second line therapy according to the latest studies conducted in China. Antibody drug conjugates was also recommended for patients with trastuzumab progression. For triple negative breast cancer, immunotherapy in early and metastatic breast cancer was highlighted and listed as new chapters in this version of guideline. For hormone receptor (HR)-positive breast cancer, cyclin dependent kinase 4/6 (CDK4/6) was recommended in different stages, especially in adjuvant therapy. There was also a new chapter for HER2-low breast cancer stratified by HR status. Conclusions: We firmly believe that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice in China and in other countries with similar situations.

Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021

Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Introduction to the Key Contents of the Chinese Society of Breast Surgery Practice Guideline 2021

Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022

To establish high-quality clinical practice guidelines and promote the standardization of diagnosis and treatment of breast disease in China

Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022

Implantable venous access port via basilic vein

Clinical practice guidelines for ductal carcinoma in situ: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

[Expert consensus on the whole-course management of implantable venous access port in the upper arm of cancer patients (2024 edition)]

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

Clinical practice guidelines for the management of central venous catheter for critically ill patients

Clinical Practice Guidelines for Visualized Percutaneous Breast Tissue Clips: Chinese Society of Breast Surgery (csbrs) Practice Guideline 2021

Interpretation of International Society for Burn Injury Practice Guidelines for Burn Care Published in 2018

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Laying equal stress on research and clinical guidelines to promote the development of breast surgery in China

Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022

Standardizing Best Nursing Practice for Implanted Ports: Applying Evidence-based Professional Guidelines to Prevent Central Line-Associated Bloodstream Infections

International experts consensus on optimal central vascular access device selection and management for patients with cancer

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

Development of clinical practice guidelines for assessment before peripherally inserted central catheter placement:AGREE evaluation

Effect and Safety of an Innovative Improved Totally implanted venous access port (TIVAP) Implantation (Noninvasive Chest Wall Implantation) via the Axillary Approach on Patients with Breast Cancer